ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
50
views
0
references
Top references
cited by
56
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,215
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
Author(s):
S Hipp
,
Y-T Tai
,
D Blanset
,
P Deegen
,
J M Wahl
,
O R Thomas
,
B Rattel
,
P J Adam
,
K C Anderson
,
M J Friedrich
Publication date:
2017-12-27
Journal:
Leukemia
Publisher:
Springer Nature
Read this article at
ScienceOpen
Publisher
Further versions
open (via crossref license)
Powered by
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Herbal Medicines Journal (Herb Med J)
Author and article information
Journal
DOI::
10.1038/leu.2016.388
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,215
CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin’s lymphoma
Authors:
C. POHL
,
R. Denfeld
,
C Renner
…
A phase 1 study of teclistamab, a humanized B-cell maturation antigen (BCMA) X CD3 bispecific antibody, for the treatment of relapsed and/or refractory multipel myeloma (RRMM)
Authors:
MV Mateos
,
S. Usmani
,
H Nahi
…
A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.
Authors:
Martin Wermke
,
Enriqueta Felip
,
Valentina Gambardella
…
See all similar
Cited by
83
Genetically engineered T cells for cancer immunotherapy
Authors:
Dan Li
,
Xue Ling Li
,
Wei-Lin Zhou
…
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Authors:
Shih-Feng Cho
,
Kenneth Anderson
,
Yu-Tzu Tai
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Authors:
Suzanne Trudel
,
Nikoletta K. Lendvai
,
Rakesh Popat
…
See all cited by
Version 1
Version 1
Version 1
Version 1